ALK
ALK is a receptor tyrosine kinase that can be altered through gene rearrangements, mutations, or amplifications. ALK alterations are well-established oncogenic drivers in lung cancer and other malignancies and guide the use of targeted kinase inhibitors.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where ALK is defined directly in the indication labeling.
Approvals defined at the solid tumor level where ALK is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report ALK as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports ALK as part of its biomarker panel.
Reports ALK as part of its biomarker panel.
Reports ALK as part of its biomarker panel.
Reports ALK as part of its biomarker panel.